tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Nail Diseases D009260 2 associated lipids
Paronychia D010304 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyspnea D004417 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Listeriosis D008088 12 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Osteomalacia D010018 5 associated lipids
Tremor D014202 15 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Vasculitis D014657 14 associated lipids
Hypothermia D007035 19 associated lipids
Parkinson Disease D010300 53 associated lipids
Down Syndrome D004314 18 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Graves Disease D006111 6 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Gout D006073 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Biliary Fistula D001658 13 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Renal Insufficiency D051437 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Swanson C et al. FK 506-based immunosuppression in clinical pancreas transplantation. 1995 Transplant. Proc. pmid:8539827
Tesi RJ et al. Conversion of pancreas transplants to FK 506 from CsA. 1995 Transplant. Proc. pmid:8539828
Burke GW et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. 1995 Transplant. Proc. pmid:8539872
Heeckt PF et al. Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. 1995 Transplantation pmid:7530870
Klintmalm GB and Gonwa TA Nephrotoxicity associated with cyclosporine and FK506. 1995 Liver Transpl Surg pmid:9346596
Gruessner RW et al. A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. 1995 Transplantation pmid:7530871
Wong PY et al. FK506 in liver transplantation for chronic hepatitis B: in vitro studies on lymphocyte activation and virus replication. 1995 Liver Transpl Surg pmid:9346613
Todo S et al. Abdominal multivisceral transplantation. 1995 Transplantation pmid:7530873
Fukuzaki T et al. A protocol with FK 506 for inducing unresponsiveness to murine islet allografts. 1995 Surgery pmid:7531371
Shapiro R et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. 1995 Transplantation pmid:7533343
Cox KL et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. 1995 Transplantation pmid:7533344
McDiarmid SV et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. 1995 Transplantation pmid:7533345
Jain AB et al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. 1995 Transplant. Proc. pmid:7533353
Rucay P et al. FK 506 as treatment of late acute rejection in liver transplant patients. 1995 Transplant. Proc. pmid:7533354
Schwartz M et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. 1995 Transplant. Proc. pmid:7533355
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
Platz KP et al. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. 1995 Transplant. Proc. pmid:7533357
Bierer BE Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. 1995 Proc. Assoc. Am. Physicians pmid:8630742
Chakraborty TK et al. Design and synthesis of a rapamycin-based high affinity binding FKBP12 ligand. 1995 Chem. Biol. pmid:9383417
Celli S et al. Mechanisms of protection from humoral rejection by a xenografted liver. 1995 Transplant. Proc. pmid:7533395
Kuroki H and Ikuta Y Nerve regeneration of vascularized rat limb allograft and functional recovery of long-term graft survivals treated by short course of FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533405
Ko S et al. Significance of newly developed liposomal FK 506 in canine liver transplantation. 1995 Transplant. Proc. pmid:7533406
Fukuzaki T et al. Induction of unresponsiveness to islet allografts with donor spleen cell inoculation followed by a single injection of FK 506. 1995 Transplant. Proc. pmid:7533407
Grochowicz PM et al. Synergism of castanospermine and FK 506. 1995 Transplant. Proc. pmid:7533408
Itoh S and Navia MA Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus). 1995 Protein Sci. pmid:8563622
Tamura K et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. 1995 Transplant. Proc. pmid:7533409
Kawano K et al. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. 1995 Transplant. Proc. pmid:7533410
Charters AR et al. Developmental expression of FK506 binding proteins and calcineurin in rat brain. 1995 Biochem. Soc. Trans. pmid:8566310
Tanabe M et al. Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 1995 Transplant. Proc. pmid:7533411
Abu-Elmagd K et al. The current status of hepatic transplantation at the University of Pittsburgh. 1995 Clin Transpl pmid:8794262
Molenaar JC [Transplantation of the small intestine]. 1995 Ned Tijdschr Geneeskd pmid:7534380
Swenson JM et al. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. 1995 J. Am. Coll. Cardiol. pmid:7534779
Sen J et al. Expression and induction of nuclear factor-kappa B-related proteins in thymocytes. 1995 J. Immunol. pmid:7534792
Hodgkiss JP and Kelly JS Only 'de novo' long-term depression (LTD) in the rat hippocampus in vitro is blocked by the same low concentration of FK506 that blocks LTD in the visual cortex. 1995 Brain Res. pmid:8821755
Komori T [The change of lymphocyte subset and effect of FK506 in experimental small bowel transplantation of rats]. 1995 Nihon Geka Gakkai Zasshi pmid:7534867
Woo J et al. Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice. 1995 Clin. Exp. Immunol. pmid:7535208
Jusko WJ et al. Pharmacokinetics of tacrolimus in liver transplant patients. 1995 Clin. Pharmacol. Ther. pmid:7535213
Winkler M and Christians U A risk-benefit assessment of tacrolimus in transplantation. 1995 Drug Saf pmid:7545405
Nowaczyk M et al. 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506). 1995 Arch. Immunol. Ther. Exp. (Warsz.) pmid:8744655
Ellis D Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. 1995 Pediatr. Nephrol. pmid:7577418
Furuke K et al. Suppression of adult T cell leukemia-derived factor/human thioredoxin induction by FK506 and cyclosporin A: a new mechanism of immune modulation via redox control. 1995 Int. Immunol. pmid:7577807
Ockenfels HM et al. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. 1995 Arch. Dermatol. Res. pmid:7541191
Victor RG et al. Presynaptic modulation of cortical synaptic activity by calcineurin. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7541535
Shapiro R et al. FK506 in pediatric kidney transplantation--primary and rescue experience. 1995 Pediatr. Nephrol. pmid:7492486
Mehta BA et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. 1995 Blood pmid:7579455
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
Ito A et al. Induction of tolerance in rat cardiac allograft model by intrathymic injection of donor bone marrow cells. 1995 Transplant. Proc. pmid:7536974
Coss MC et al. Molecular cloning, DNA sequence analysis, and biochemical characterization of a novel 65-kDa FK506-binding protein (FKBP65). 1995 J. Biol. Chem. pmid:7493967
Hemenway C FK506 in bone marrow transplantation. 1995 Blood pmid:7579473
Büttemeyer R et al. Peripheral nerve allotransplant immunosuppressed with FK 506: preliminary results. 1995 Transplant. Proc. pmid:7536979
Lee MJ et al. Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats. 1995 Pharm. Res. pmid:7494802
Yamamoto M et al. Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. 1995 Anticancer Drugs pmid:7579561
Venkataramanan R et al. Clinical pharmacokinetics of tacrolimus. 1995 Clin Pharmacokinet pmid:8787947
Arita S et al. Effect of FK 506 in experimental pancreas transplantation. 1995 Transplant. Proc. pmid:7536980
Zhao Y and Iwata M Cross-linking of the TCR-CD3 complex with CD4, CD8 or LFA-1 induces an anti-apoptotic signal in thymocytes: the signal is canceled by FK506. 1995 Int. Immunol. pmid:7495746
O'Gorman MA et al. Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients. 1995 Clin Transplant pmid:7579739
Aono T et al. Minimal threshold of FK 506 for enhancing liver regeneration in thymectomized rats. 1995 Transplant. Proc. pmid:7536981
Saito T et al. In situ dephosphorylation of tau by protein phosphatase 2A and 2B in fetal rat primary cultured neurons. 1995 FEBS Lett. pmid:7498550
Kanamaru A et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. 1995 Bone Marrow Transplant. pmid:7581086
Iwabuchi T et al. Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth. 1995 J. Dermatol. Sci. pmid:7537082
Antoni FA et al. Calcineurin feedback inhibition of agonist-evoked cAMP formation. 1995 J. Biol. Chem. pmid:7499291
Koehler MT et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:7581088
Arnold JC and Theilmann L [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation]. 1995 Z Gastroenterol pmid:7502559
Osman A et al. Schistosoma mansoni: characterization of p50, an immunophilin. 1995 Exp. Parasitol. pmid:7537219
Tanida I et al. Cooperation of calcineurin and vacuolar H(+)-ATPase in intracellular Ca2+ homeostasis of yeast cells. 1995 J. Biol. Chem. pmid:7537264
Koch K et al. The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant. 1995 J. Med. Chem. pmid:7537331
Corey HE et al. Renal allograft rejection in children and young adults: the Banff classification. 1995 Pediatr. Nephrol. pmid:7543274
Griffith JP et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. 1995 Cell pmid:7543369
Prud'homme GJ et al. Effects of cyclosporin A, rapamycin, and FK520 on peripheral T-cell deletion and anergy. 1995 Cell. Immunol. pmid:7543371
Migita K et al. FK506 augments activation-induced programmed cell death of T lymphocytes in vivo. 1995 J. Clin. Invest. pmid:7543492
Rodriguez Rilo HL et al. Rapid hair regrowth in refractory alopecia universalis associated with autoimmune disease following liver transplantation and tacrolimus (FK506) therapy. 1995 Transplantation pmid:7539169
Lhoëst G et al. The in vitro immunosuppressive activity of the C15-demethylated metabolite of FK-506 is governed by ring- and open-chain tautomerism effects. 1995 J. Pharmacol. Exp. Ther. pmid:7543569
Schleibner S et al. FK 506 versus cyclosporin in the prevention of renal allograft rejection--European pilot study: six-week results. 1995 Transpl. Int. pmid:7539270
Textor SC et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. 1995 Kidney Int. pmid:7543625
Ko S et al. The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. 1995 Transplantation pmid:7539553
Dollinger MM et al. Tacrolimus and cardiotoxicity in adult liver transplant recipients. 1995 Lancet pmid:7543645
Fealy MJ et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. 1995 Transplantation pmid:7539555
Romero DF et al. Rapamycin: a bone sparing immunosuppressant? 1995 J. Bone Miner. Res. pmid:7543725
Hisatomi K et al. Changes in the mononuclear cell subpopulations of rat cardiac transplant recipients administered FK506 for the treatment of ongoing rejection. 1995 Surg. Today pmid:7539647
Kinoshita I et al. Myoblast allotransplantation in primates. 1995 Muscle Nerve pmid:7544871
Monsour HP et al. Renal insufficiency and hypertension as long-term complications in liver transplantation. 1995 Semin. Liver Dis. pmid:7544917
Varela E [Small bowel transplantation]. 1995 Acta Gastroenterol. Latinoam. pmid:7544939
Taler SJ et al. Loss of nocturnal blood pressure fall after liver transplantation during immunosuppressive therapy. 1995 Am. J. Hypertens. pmid:7544983
Morris RE and Brown BW Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations. 1995 Lancet pmid:7475764
Starzl TE et al. Randomised trialomania? The multicentre liver transplant trials of tacrolimus. 1995 Lancet pmid:7475777
Teague S Lessons from molecular matchmakers. 1995 Nat. Struct. Biol. pmid:7545076
Milad M et al. Interaction of the progesterone receptor with binding proteins for FK506 and cyclosporin A. 1995 Mol. Endocrinol. pmid:7476967
Ito T et al. Immunosuppressive agents induce the reduction of local pancreatic blood flow. 1995 Pancreas pmid:7545292
Zhang J and Steiner JP Nitric oxide synthase, immunophilins and poly(ADP-ribose) synthetase: novel targets for the development of neuroprotective drugs. 1995 Neurol. Res. pmid:7477744
Han CW et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. 1995 Bone Marrow Transplant. pmid:7545487
Jindal RM and Popescu I Renal dysfunction associated with liver transplantation. 1995 Postgrad Med J pmid:7479462
Yeh WC et al. Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479941
Yeh WC et al. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479942
Shaw KT et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479966
Holsinger LJ et al. Signal transduction in T lymphocytes using a conditional allele of Sos. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7568223
Faerman CH and Karplus PA Consensus preferred hydration sites in six FKBP12-drug complexes. 1995 Proteins pmid:8539241
Groth CG Immunosuppressive regimens of tomorrow. 1995 Transplant. Proc. pmid:8539797
Hariharan S et al. Conversion from cyclosporine to tacrolimus after pancreas transplantation. 1995 Transplant. Proc. pmid:8539799
Henley SE et al. Lipids following pancreas transplantation in recipients receiving FK 506. 1995 Transplant. Proc. pmid:8539809
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823